Immunostimulants and prevention of recurrent respiratory tract infections
- PMID: 24152832
Immunostimulants and prevention of recurrent respiratory tract infections
Abstract
Recurrent respiratory tract infections (RRTIs) are very common in children and a major challenge for pediatricians. They affect the children's quality of life, cause absences from school and lost parental working days, and repeated medical examinations, hospital admissions as well as antibiotic therapies lead to high costs for society. Given their prevalence and clinical importance, various prevention strategies have been developed. One of the most widely used is the administration of immunostimulants: i.e. molecules of bacterial or synthetic origin that interact with immunological mechanisms in vitro and in vivo. A number of studies have investigated their effects on cellular and innate immunity, and their clinical efficacy, but there is no consensus as to their real usefulness. The main aim of this review is to analyse the available data concerning the activity and efficacy of immunostimulants in preventing pediatric RRTIs. The majority of studies have shown that the number of infections decreases after immunostimulant treatment, but they are affected by various methodological weaknesses. Further studies are urgently needed to confirm whether, when and which immunostimulants should be used.
Similar articles
-
Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials.Int Immunopharmacol. 2019 Feb;67:35-45. doi: 10.1016/j.intimp.2018.11.043. Epub 2018 Dec 7. Int Immunopharmacol. 2019. PMID: 30530167 Review.
-
Pidotimod may prevent recurrent respiratory infections in children.Minerva Pediatr. 2014 Oct;66(5):363-7. Minerva Pediatr. 2014. PMID: 25253184 Clinical Trial.
-
Pidotimod for the prevention of acute respiratory infections in healthy children entering into daycare: A double blind randomized placebo-controlled study.Pharmacol Res. 2015 Jul;97:79-83. doi: 10.1016/j.phrs.2015.04.007. Epub 2015 Apr 27. Pharmacol Res. 2015. PMID: 25931316 Clinical Trial.
-
Pidotimod: a reappraisal.Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):255-62. doi: 10.1177/039463200902200201. Int J Immunopathol Pharmacol. 2009. PMID: 19505378 Review.
-
Compilation and meta-analysis of randomized placebo-controlled clinical trials on the prevention of respiratory tract infections in children using immunostimulants.J Investig Allergol Clin Immunol. 2001;11(4):235-46. J Investig Allergol Clin Immunol. 2001. PMID: 11908811
Cited by
-
The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3).Int J Mol Sci. 2019 Oct 24;20(21):5287. doi: 10.3390/ijms20215287. Int J Mol Sci. 2019. PMID: 31653015 Free PMC article.
-
Paediatric Recurrent Ear, Nose and Throat Infections and Complications: Can We Do More?Infect Dis Ther. 2020 Jun;9(2):275-290. doi: 10.1007/s40121-020-00289-3. Epub 2020 Apr 24. Infect Dis Ther. 2020. PMID: 32333286 Free PMC article. Review.
-
Role of biofilm in children with recurrent upper respiratory tract infections.Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):421-9. doi: 10.1007/s10096-014-2261-1. Epub 2014 Oct 16. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25318897 Review.
-
Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia.J Transl Med. 2015 Sep 3;13:288. doi: 10.1186/s12967-015-0649-z. J Transl Med. 2015. PMID: 26335787 Free PMC article. Clinical Trial.
-
A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections.J Transl Med. 2019 Aug 23;17(1):284. doi: 10.1186/s12967-019-2040-y. J Transl Med. 2019. PMID: 31443716 Free PMC article. Clinical Trial.